JP2017514496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514496A5 JP2017514496A5 JP2016566228A JP2016566228A JP2017514496A5 JP 2017514496 A5 JP2017514496 A5 JP 2017514496A5 JP 2016566228 A JP2016566228 A JP 2016566228A JP 2016566228 A JP2016566228 A JP 2016566228A JP 2017514496 A5 JP2017514496 A5 JP 2017514496A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- rodent
- mouse
- human
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims 58
- 108700024394 Exon Proteins 0.000 claims 24
- 101100328540 Homo sapiens C3 gene Proteins 0.000 claims 21
- 101100328542 Mus musculus C3 gene Proteins 0.000 claims 21
- 241000699666 Mus <mouse, genus> Species 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 101100440311 Homo sapiens C5 gene Proteins 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 101100440312 Mus musculus C5 gene Proteins 0.000 claims 10
- 101150069146 C5 gene Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 101150071258 C3 gene Proteins 0.000 claims 5
- 230000024203 complement activation Effects 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 238000011577 humanized mouse model Methods 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- -1 small molecule chemical compound Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988581P | 2014-05-05 | 2014-05-05 | |
| US61/988,581 | 2014-05-05 | ||
| US201462067836P | 2014-10-23 | 2014-10-23 | |
| US62/067,836 | 2014-10-23 | ||
| PCT/US2015/029111 WO2015171523A1 (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514496A JP2017514496A (ja) | 2017-06-08 |
| JP2017514496A5 true JP2017514496A5 (cg-RX-API-DMAC7.html) | 2018-06-28 |
| JP6598798B2 JP6598798B2 (ja) | 2019-10-30 |
Family
ID=53177902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566228A Active JP6598798B2 (ja) | 2014-05-05 | 2015-05-04 | ヒト化ｃ５およびｃ３動物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9795121B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3636073B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6598798B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102461511B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106659146B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015256299C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016025751A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2946412C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2968749T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL248481B (cg-RX-API-DMAC7.html) |
| MA (1) | MA51519A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2016014504A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2020103811A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10202003996YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015171523A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| AU2015256299C1 (en) | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| EP3407915A4 (en) * | 2016-01-25 | 2019-11-20 | President and Fellows of Harvard College | METHOD AND COMPOSITIONS FOR DETECTING AND TREATING SCHIZOPHRENIA |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| MX2019010219A (es) * | 2017-02-27 | 2020-02-07 | Regeneron Pharma | Modelo humanizado de trastornos renales y hepáticos. |
| KR102782655B1 (ko) | 2017-07-06 | 2025-03-14 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| CN107736281A (zh) * | 2017-09-29 | 2018-02-27 | 中国水产科学研究院珠江水产研究所 | 一种利用益生菌发酵酱油渣防治池塘养殖鳜鱼寄生虫的方法 |
| KR20240128129A (ko) * | 2017-09-29 | 2024-08-23 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 C1q 복합체를 발현하는 비인간 동물 |
| EP4276185A3 (en) * | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| IL275264B1 (en) | 2017-12-13 | 2025-10-01 | Regeneron Pharma | Anti-C5 antibody combinations and their uses |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| KR102503356B1 (ko) | 2018-03-19 | 2023-02-24 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
| AU2019248557A1 (en) | 2018-04-03 | 2020-09-24 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| FI3823443T3 (fi) | 2018-07-16 | 2024-07-25 | Regeneron Pharma | Ditra-taudin jyrsijämallit ja niiden käyttö |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| US12098190B2 (en) * | 2018-09-06 | 2024-09-24 | The Trustees Of The University Of Pennsylvania And | Humanized anti-C5 antibodies and uses thereof |
| SG11202104237YA (en) | 2019-01-16 | 2021-05-28 | Regeneron Pharma | Methods for identifying free thiols in proteins |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| CA3137907A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| CA3135004A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| JP7635213B2 (ja) | 2019-09-24 | 2025-02-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーの使用および再生のためのシステムおよび方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MY207613A (en) | 2019-11-25 | 2025-03-06 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| JP2023542820A (ja) | 2020-08-31 | 2023-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略 |
| EP4221496A1 (en) | 2020-10-01 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Rodent animals expressing human cr1 |
| US12239687B2 (en) | 2020-11-25 | 2025-03-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| WO2022159432A1 (en) | 2021-01-20 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| US20230110811A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | pH METER CALIBRATION AND CORRECTION |
| AU2022376179A1 (en) | 2021-10-26 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| US20240198253A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445135A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 液態蛋白質組成物穩定性之建模方法 |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| AU2024265540A1 (en) | 2023-05-01 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| TW202528736A (zh) | 2023-09-08 | 2025-07-16 | 美商再生元醫藥公司 | 用於評估層析管柱完整性的方法及系統 |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025122669A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized complement factor b gene |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
| GB9521943D0 (en) | 1995-10-26 | 1996-01-03 | Univ Hertfordshire | Coded particles for process sequence tracking in combinatorial compound library preparation |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| WO2005060739A1 (en) * | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| DK1713503T3 (da) | 2004-02-10 | 2013-11-04 | Univ Colorado Regents | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| JP2009523237A (ja) | 2006-01-11 | 2009-06-18 | ノヴォ ノルディスク アクティーゼルスカブ | 改良された球状コード化ビーズ |
| EP2254911B1 (en) * | 2008-02-20 | 2015-11-25 | Novo Nordisk A/S | Humanized anti-c5ar antibodies |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| KR102256316B1 (ko) | 2011-02-15 | 2021-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 ｍ－ｃｓｆ 마우스 |
| CA2853731C (en) | 2011-10-28 | 2021-05-18 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| ES2741649T3 (es) | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| CN108782459B (zh) | 2012-09-07 | 2021-11-05 | 再生元制药公司 | 经遗传修饰的非人动物及其使用方法 |
| IL299887B2 (en) | 2012-11-05 | 2024-09-01 | Regeneron Pharma | Genetically modified non-human animals and methods of use thereof |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| ES2715949T3 (es) | 2013-10-15 | 2019-06-07 | Regeneron Pharma | Animales con IL-15 humanizada |
| EP3430898A1 (en) | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| AU2015256299C1 (en) * | 2014-05-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Humanized C5 and C3 animals |
-
2015
- 2015-05-04 AU AU2015256299A patent/AU2015256299C1/en not_active Ceased
- 2015-05-04 KR KR1020167032659A patent/KR102461511B1/ko active Active
- 2015-05-04 RU RU2020103811A patent/RU2020103811A/ru unknown
- 2015-05-04 BR BR112016025751A patent/BR112016025751A2/pt not_active Application Discontinuation
- 2015-05-04 SG SG10202003996YA patent/SG10202003996YA/en unknown
- 2015-05-04 SG SG11201608696RA patent/SG11201608696RA/en unknown
- 2015-05-04 EP EP19211905.5A patent/EP3636073B1/en active Active
- 2015-05-04 CA CA2946412A patent/CA2946412C/en active Active
- 2015-05-04 CN CN201580034127.8A patent/CN106659146B/zh active Active
- 2015-05-04 ES ES19211905T patent/ES2968749T3/es active Active
- 2015-05-04 CA CA3225091A patent/CA3225091A1/en active Pending
- 2015-05-04 ES ES15722639T patent/ES2779070T3/es active Active
- 2015-05-04 EP EP23202404.2A patent/EP4317445A3/en not_active Withdrawn
- 2015-05-04 MX MX2016014504A patent/MX2016014504A/es active IP Right Grant
- 2015-05-04 EP EP15722639.0A patent/EP3142483B1/en active Active
- 2015-05-04 WO PCT/US2015/029111 patent/WO2015171523A1/en not_active Ceased
- 2015-05-04 RU RU2016146390A patent/RU2713327C2/ru active
- 2015-05-04 MA MA051519A patent/MA51519A/fr unknown
- 2015-05-04 US US14/703,818 patent/US9795121B2/en not_active Expired - Fee Related
- 2015-05-04 MX MX2019013850A patent/MX386644B/es unknown
- 2015-05-04 JP JP2016566228A patent/JP6598798B2/ja active Active
-
2016
- 2016-10-25 IL IL248481A patent/IL248481B/en active IP Right Grant
-
2017
- 2017-07-26 US US15/660,833 patent/US10492477B2/en active Active
-
2018
- 2018-07-02 US US16/025,377 patent/US10524458B2/en active Active
-
2019
- 2019-10-21 US US16/658,541 patent/US11178860B2/en not_active Expired - Fee Related
-
2021
- 2021-10-20 US US17/505,834 patent/US20220132818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514496A5 (cg-RX-API-DMAC7.html) | ||
| RU2020103811A (ru) | Гуманизированные животные по с5 и с3 | |
| EP4414988A3 (en) | Methods, systems, and software for identifying bio-molecules using models of multiplicative form | |
| PH12016500342A1 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| PH12017501887A1 (en) | Pesticidal genes and methods of use | |
| JP2014039567A5 (cg-RX-API-DMAC7.html) | ||
| BR112016025745A2 (pt) | roedor, camundongo, métodos para produção de um roedor e de um camundongo e para triagem de antagonista | |
| AR102888A1 (es) | Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47 | |
| JP2015523863A5 (cg-RX-API-DMAC7.html) | ||
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| BR112016006261A2 (pt) | camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas | |
| MY185881A (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
| HRP20200613T1 (hr) | Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt | |
| EP4345163A3 (en) | Genetic engineering of non-human animals for the production of chimeric antibodies | |
| MX387036B (es) | Animales con dipeptidil peptidasa iv (dpp4) humanizada | |
| AR072495A1 (es) | Secuencia reguladora de las plantas proveniente de un gen de maiz | |
| PH12018501338A1 (en) | Pesticidal genes and methods of use | |
| MX2017008367A (es) | Genes pesticidas y metodos de uso. | |
| BR112017012389A2 (pt) | supressão de rnai parental de gene kruppel para controlar pragas de coleóptero | |
| EA201690634A1 (ru) | Новая гетеро-трансгликозилаза и ее применение | |
| PH12017502420A1 (en) | Pesticidal genes and methods of use | |
| WO2014146181A3 (pt) | Promotor específico de folhas, gene quimérico, vetor de recombinante, planta ou parte de planta transformada e métodos contendo promotor específico de folhas para modificar a expressão de genes de interesse em plantas | |
| NZ726602B2 (en) | Humanized c5 and c3 animals | |
| NZ763860B2 (en) | Humanized c5 and c3 animals | |
| Triviño et al. | SOFTvenom: an omics drug discovery approach from animal venoms |